Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Prevention Study in Adult Patients Suffering From Migraine Headaches

ClinicalTrials.gov ID: NCT00742209

Public ClinicalTrials.gov record NCT00742209. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 1:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache

Study identification

NCT ID
NCT00742209
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
XenoPort, Inc.
Industry
Enrollment
526 participants

Conditions and interventions

Interventions

  • GSK1838262 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2008
Primary completion
May 31, 2010
Completion
May 31, 2010
Last update posted
Jul 21, 2013

2008 – 2010

United States locations

U.S. sites
45
U.S. states
22
U.S. cities
40
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35233
GSK Investigational Site Phoenix Arizona 85016
GSK Investigational Site Phoenix Arizona 85023
GSK Investigational Site Anaheim California 92801
GSK Investigational Site Newport Beach California 92660
GSK Investigational Site Redlands California 92374
GSK Investigational Site San Francisco California 94109
GSK Investigational Site Santa Monica California 90404
GSK Investigational Site Westlake Village California 91361
GSK Investigational Site Colorado Springs Colorado 80904
GSK Investigational Site Colorado Springs Colorado 80909
GSK Investigational Site Denver Colorado 80239
GSK Investigational Site DeLand Florida 32720
GSK Investigational Site Sunrise Florida 33351
GSK Investigational Site West Palm Beach Florida 33407
GSK Investigational Site Atlanta Georgia 30308
GSK Investigational Site Stockbridge Georgia 30281
GSK Investigational Site Chicago Illinois 60642
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Kalamazoo Michigan 49009
GSK Investigational Site Golden Valley Minnesota 55422
GSK Investigational Site Kansas City Missouri 64111
GSK Investigational Site Springfield Missouri 65807
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Las Vegas Nevada 89119
GSK Investigational Site Albany New York 12206
GSK Investigational Site Greensboro North Carolina 27405
GSK Investigational Site Raleigh North Carolina 27607
GSK Investigational Site Raleigh North Carolina 27609
GSK Investigational Site Cleveland Ohio 44195
GSK Investigational Site West Chester Ohio 45069
GSK Investigational Site Westerville Ohio 43081
GSK Investigational Site Philadelphia Pennsylvania 19107
GSK Investigational Site Philadelphia Pennsylvania 19139
GSK Investigational Site Pittsburgh Pennsylvania 15236
GSK Investigational Site Charleston South Carolina 29412
GSK Investigational Site Memphis Tennessee 38018
GSK Investigational Site Nashville Tennessee 37203
GSK Investigational Site Houston Texas 77004
GSK Investigational Site San Antonio Texas 78205
GSK Investigational Site Salt Lake City Utah 84109
GSK Investigational Site Salt Lake City Utah 84121
GSK Investigational Site Alexandria Virginia 22311
GSK Investigational Site Seattle Washington 98195
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00742209, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 21, 2013 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00742209 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →